Wellbeing Digital Sciences Inc. (KONEF)

Overview

KetamineOne Capital Limited represents a forward-looking approach in the wellness industry, specifically focusing on the burgeoning field of ketamine assisted therapy and psychedelic medicines. Initially founded in 2017 and operating from Vancouver, Canada, the company has undergone significant transformation, notably changing its name from Myconic Capital Corp. to KetamineOne Capital Limited in June 2021. This rebranding mirrors the company's commitment to pioneering in the psychedelic wellness sector, mainly through the operation of healthcare clinics across North America. KetamineOne aims to position itself at the forefront of next-generation wellness solutions, emphasizing innovative treatments that harness ketamine and other psychedelic substances for mental health and wellbeing.

Products and Services

• Ketamine Assisted Therapy

  This innovative treatment combines traditional psychotherapy with ketamine, a legal psychedelic medication, to address various mental health issues. Ketamine Assisted Therapy is gaining recognition for its potential to provide rapid relief from symptoms of depression, anxiety, and PTSD, among other conditions, offering a novel approach for patients for whom conventional treatments have been ineffective.

• Psychedelic Medicines

  In its pursuit of advancing wellness and mental health treatment, KetamineOne is also exploring the therapeutic use of broader psychedelic medicines. These include, but are not limited to, psilocybin, MDMA, and LSD, under legal and regulated frameworks. Such substances are being investigated for their efficacy in treating a range of mental health disorders, harnessing their potential to alter perception, mood, and cognitive processes in therapeutic settings.

• Healthcare Clinics

  Operating a network of healthcare clinics across North America, KetamineOne provides a critical infrastructure necessary for delivering its innovative treatments. These clinics serve as the venues for ketamine assisted therapy sessions, as well as research and application of other psychedelic medicines under professional supervision. They function as both treatment centers and pivotal research hubs, contributing to the growing body of evidence that supports the efficacy and safety of psychedelic therapies.